Ventyx Biosciences, Inc.

As of April 2, 2024, Ventyx Biosciences, Inc. shows a mildly bearish trend due to daily moving averages, while weekly MACD remains bullish and monthly indicators present mixed signals, indicating cautious bearish sentiment in the short term.

Ventyx Biosciences, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $27 million and a market cap of $156.55 million. Key financial metrics include a P/E ratio of NA, a dividend yield of 0.00%, and a return on equity of -53.40%.

As of Jun 18, Ventyx Biosciences, Inc. has a market capitalization of 156.55 million, with net sales of 0.00 million and a net profit of -123.99 million over the latest four quarters. The company reported shareholder's funds of 254.04 million and total assets of 278.67 million as of Dec 24.